Drug Trial Radar · NCT06669533
Use Misoprostol to Optimize Prevention of Cervical Cancer
Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
840
Planned (sponsor's estimate)
Start
Feb 25, 2025
Primary completion
Nov 4, 2027
Study completion Nov 11, 2028
Sponsor
- Lead sponsor
- University of Alabama at BirminghamAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Cameroon Baptist Convention Health; National Cancer Institute (NCI)
- First posted
- Nov 1, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Screening
- FDA-regulated drug
- No
- Who can join
- Female only, from 25 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a double-blind randomized controlled trial of 420 non-pregnant women undergoing cancer screening by visual inspection with acetic acid (VIA) who have Type 3 transformation zone (TZ) and randomized to receive either Misoprostol or placebo.
Conditions
- Cervical Cancers
Interventions
PlaceboDrug
Participants will receive placebo (3 tablets) administered vaginally 2-3 hours and 4-6 hours prior to visual inspection with acetic acid (VIA).
MisoprostolDrug
Participants will receive 600 mcg misoprostol (3 tablets) administered vaginally 2-3 hours and 4-6 hours prior to visual inspection with acetic acid (VIA).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Conversion rate from Type 3 transformation zone (TZ) to Types 1 or 2Time frame: Approximately 2-3 hours and approximately 4-6 hours since drug administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cameroon Baptist Convention Health Core, EtougEbe Baptist Hospital Yaoundé
Yaoundé, Center Region, Cameroon · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.